Our comprehensive and highly sensitive and specific range of tests can detect genetic alterations that drive tumor growth in all types of cancer. We are highly experienced in characterizing mechanisms of action of targeted therapies, particularly against epidermal growth factor receptor (EGFR), as well as other tyrosine kinase inhibitors.
